We entered into a landmark ten-year collaboration agreement with Moderna Inc. to manufacture the drug substance for Moderna’s COVID-19 Vaccine, alongside other mRNA-based collaboration projects from Moderna’s innovation pipeline.
We expanded our global particle engineering network and added new dedicated development capacity for spray dry processing.
We reported strong operational performance maintained during COVID-19, with Pharma Biotech business driving group sales growth and margin improvement in H1 2020. In addition, the Board of Directors reviewed strategic options for the long-term future of the LSI business and decided to divest the LSI segment via a sale process.
We announced that our Ibex® Dedicate facility will support the commercial manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate (ABC) for retinal diseases.
We qualified the Cocoon® Platform towards clinical and commercial readiness and treated the first patient at Sheba Medical Center (IL) with an autologous CAR-T therapy, manufactured using the Cocoon® Platform.
We provided details of our new structural design, cultural values and external reporting during Investor Update event.
We announced an expansion of our capsule manufacturing capacity.
We announced an agreement to manufacture AstraZeneca’s COVID-19 long-acting antibody combination.
Our Diversity and Inclusion global taskforce lead team was formed.